Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1

Genome Medicine

Volumn 7, Issue 1, 2015, Pages

  Seitz, Tina ^a   Stalmann, Robert ^a   Dalila, Nawar ^a   Chen, Jiayin ^a   Pojar, Sherin ^a   Dos Santos Pereira, Joao N ^a   Krätzner, Ralph ^a   Brockmöller, Jürgen ^a   Tzvetkov, Mladen V ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ORGANIC CATION TRANSPORTER 1;

AFRICA SOUTH OF THE SAHARA; AFRICAN AMERICAN; AMERICAN INDIAN; AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; CAUCASIAN; CELLULAR DISTRIBUTION; CENTRAL ASIAN; CONFOCAL MICROSCOPY; CONTROLLED STUDY; EAST ASIAN; ENZYME METABOLISM; ENZYME SPECIFICITY; ETHNICITY; EUROPEAN; EUROPEAN AMERICAN; FLUORESCENCE SPECTROSCOPY; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCATION; GENE MAPPING; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLYCOSYLATION; HAPLOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MEXICAN; MIDDLE EAST; MOLECULAR EVOLUTION; NEXT GENERATION SEQUENCING; NORMAL HUMAN; NORTH AFRICA; OCEANIAN; OCT1 GENE; PACIFIC ISLANDER; POPULATION GENETICS; PRIORITY JOURNAL; PROMOTER REGION; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AMERICAN; WESTERN BLOTTING;

EID: 84936131283     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/s13073-015-0172-0     Document Type: Article

References (51)

1. Chen L, Shu Y, Liang X, Chen EC, Yee SW, Zur AA, et al. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A. 2014;111:9983-8.
2. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117:1422-31.
3. Tzvetkov MV, dos Santos Pereira JN, Meineke I, Saadatmand AR, Stingl JC, Brockmoller J. Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol. 2013;86:666-78.
4. Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, Brockmoller J. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J. 2012;12:22-9.
5. Tzvetkov MV, Saadatmand AR, Lotsch J, Tegeder I, Stingl JC, Brockmoller J. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther. 2011;90:143-50.
6. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997;51:913-21.
7. Herraez E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM, et al. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology. 2013;58:1065-73.
8. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009;50:1227-40.
9. Tu M, Sun S, Wang K, Peng X, Wang R, Li L, et al. Organic cation transporter 1 mediates the uptake of monocrotaline and plays an important role in its hepatotoxicity. Toxicology. 2013;311:225-30.
10. Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E, et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics. 2002;12:591-5.
11. Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A. 2003;100:5902-7.
12. Fukuda T, Chidambaran V, Mizuno T, Venkatasubramanian R, Ngamprasertwong P, Olbrecht V, et al. OCT1 genetic variants influence the pharmacokinetics of morphine in children. Pharmacogenomics. 2013;14:1141-51.
13. Nies A, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), In Vitro and In Vivo evidence for the importance in drug therapy. Handb Exp Pharmacol. 2011;201:105-67.
14. Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, et al. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol. 2001;21:5471-7.
15. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002;302:510-5.
16. Leabman MK, Huang CC, DeYoung J, Carlson EJ, Taylor TR, de la Cruz M, et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A. 2003;100:5896-901.
17. Chen L, Takizawa M, Chen E, Schlessinger A, Segenthelar J, Choi JH, et al. Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther. 2010;335:42-50.
18. Itoda M, Saito Y, Maekawa K, Hichiya H, Komamura K, Kamakura S, et al. Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab Pharmacokinet. 2004;19:308-12.
19. Saito S, Iida A, Sekine A, Ogawa C, Kawauchi S, Higuchi S, et al. Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population. J Hum Genet. 2002;47:576-84.
20. Sakata T, Anzai N, Shin HJ, Noshiro R, Hirata T, Yokoyama H, et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun. 2004;313:789-93.
21. Takeuchi A, Motohashi H, Okuda M, Inui K. Decreased function of genetic variants, Pro283Leu and Arg287Gly, in human organic cation transporter hOCT1. Drug Metab Pharmacokinet. 2003;18:409-12.
22. Cann HM, de Toma C, Cazes L, Legrand MF, Morel V, Piouffre L, et al. A human genome diversity cell line panel. Science. 2002;296:261-2.
23. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009;86:299-306.
24. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56-65.
25. Saadatmand AR, Tadjerpisheh S, Brockmoller J, Tzvetkov MV. The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Biochem Pharmacol. 2012;83:1427-34.
26. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978-89.
27. Excoffier L, Laval G, Schneider S. Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online. 2005;1:47-50.
28. HGDP-CEPH Database. Available at: http://www.cephb.fr/en/hgdp_panel.php .
29. Schomig E, Lazar A, Grundemann D. Extraneuronal monoamine transporter and organic cation transporters 1 and 2: a review of transport efficiency. Handb Exp Pharmacol. 2006;175:151-80.
30. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics. 2008;9:19-33.
31. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007;17:93-101.
32. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther. 2010;87:130-3.
33. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63:157-81.
34. Group SC, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008;359:789-99.
35. Urban TJ, Sebro R, Hurowitz EH, Leabman MK, Badagnani I, Lagpacan LL, et al. Functional genomics of membrane transporters in human populations. Genome Res. 2006;16:223-30.
36. Sadhasivam S, Krekels EH, Chidambaran V, Esslinger HR, Ngamprasertwong P, Zhang K, et al. Morphine clearance in children: does race or genetics matter? J Opioid Manag. 2012;8:217-26.
37. Li JZ, Absher DM, Tang H, Southwick AM, Casto AM, Ramachandran S, et al. Worldwide human relationships inferred from genome-wide patterns of variation. Science. 2008;319:1100-4.
38. Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet. 1997;60:265-71.
39. Masson F, Talon R, Montel MC. Histamine and tyramine production by bacteria from meat products. Int J Food Microbiol. 1996;32:199-207.
40. Pechanek U, Pfannhauser W, Woidich H. Untersuchung fiber den Gehalt biogener Amine in vier Gruppen von Lebensmitteln des iisterreichischen Marktes. Zeitschift for Lebensmittel Untersuchung und Forschung. 1983;176:335-40.
41. Grimsby J, Lan NC, Neve R, Chen K, Shih JC. Tissue distribution of human monoamine oxidase A and B mRNA. J Neurochem. 1990;55:1166-9.
42. Bf R. Pyrrolizidinalkaloide in Kräutertees und Tees 018/2013 edition. Berlin: BfR - Bundesinstitut für Risikobewertung; 2013.
43. Fu PP, Xia Q, Lin G, Chou MW. Pyrrolizidine alkaloids-genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev. 2004;36:1-55.
44. Worldwide distribution map of Crotalaria retusa (rattleweed). Available at: www.cabi.org/isc/datasheet/87408 .
45. Li L, Tu M, Yang X, Sun S, Wu X, Zhou H, et al. The contribution of human OCT1, OCT3, and CYP3A4 to nitidine chloride-induced hepatocellular toxicity. Drug Metab Dispos. 2014;42:1227-34.
46. Tu M, Li L, Lei H, Ma Z, Chen Z, Sun S, et al. Involvement of organic cation transporter 1 and CYP3A4 in retrorsine-induced toxicity. Toxicology. 2014;322:34-42.
47. Liu H, Prugnolle F, Manica A, Balloux F. A geographically explicit genetic model of worldwide human-settlement history. Am J Hum Genet. 2006;79:230-7.
48. Lourenco AE, Santos RV, Orellana JD, Coimbra Jr CE. Nutrition transition in Amazonia: obesity and socioeconomic change in the Surui Indians from Brazil. Am J Hum Biol. 2008;20:564-71.
49. Keller T, Egenberger B, Gorboulev V, Bernhard F, Uzelac Z, Gorbunov D, et al. The large extracellular loop of organic cation transporter 1 influences substrate affinity and is pivotal for oligomerization. J Biol Chem. 2011;286:37874-86.
50. Koepsell H. Substrate recognition and translocation by polyspecific organic cation transporters. Biol Chem. 2011;392:95-101.
51. ModBase: database of comparative protein structure models. Available at: http://modbase.compbio.ucsf.edu .